Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.
about
Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B.Unveiling the roles of HBV polymerase for new antiviral strategiesStructure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase.Antiviral therapies: focus on hepatitis B reverse transcriptaseEntecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors.Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy.Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response.Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.
P2860
Q35221837-0EFE2281-B00B-4536-B6B4-9C5832439836Q35441503-04B3DD35-2016-4C7E-BCA7-BC88D4D6C7A4Q36244591-B6D797BF-3BAA-4EF6-86FF-5DE50E8431CCQ36467514-D0B04460-88CE-4E1E-833A-106B5929A3B3Q37964712-313197C1-5F9D-4F8A-AA17-DF76D005EAECQ38151881-DCC1597C-F8D3-4EBC-89B1-0B2DA507E979Q39985036-8F9AA628-D555-490E-B66B-62F93B931632Q42148791-6B9E28C4-CD3A-4B73-B1A3-C5C1CF29C248Q42232786-1CBCB4DA-3F5E-428B-8CF7-BBD02264846FQ44087733-A9F24119-9DB1-449B-AC3A-A60EABED7F7BQ47548606-54D9A6E1-FDD9-46F4-B18F-76EED26C8813
P2860
Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Mechanism of entecavir resista ...... molecular docking simulation.
@ast
Mechanism of entecavir resista ...... molecular docking simulation.
@en
type
label
Mechanism of entecavir resista ...... molecular docking simulation.
@ast
Mechanism of entecavir resista ...... molecular docking simulation.
@en
prefLabel
Mechanism of entecavir resista ...... molecular docking simulation.
@ast
Mechanism of entecavir resista ...... molecular docking simulation.
@en
P2093
P2860
P356
P1476
Mechanism of entecavir resista ...... d molecular docking simulation
@en
P2093
Etsuro Orito
Fuat Kurbanov
Gotaro Yamada
Kohsaku Sakaguchi
Man-Fung Yuen
Manami Inoue
Masashi Mizokami
Michio Sata
Motokazu Mukaide
Osamu Yokosuka
P2860
P304
P356
10.1128/AAC.01061-09
P407
P577
2009-11-23T00:00:00Z